在老年人中存在阳离子缺口.

Same author

Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET.

ESMO open·2025

Same author

Comparative evaluation of isoflurane and sevoflurane in avian patients.

Veterinary world·2021

Same author

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Same author

Patients with COVID-19: are current isolation guidelines effective enough?

Public health·2020

Same author

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Blood·2020

Same author

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia.

Blood cancer journal·2017

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

相关实验视频

在老年人中存在阳离子缺口.

相关概念视频

Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET.

Comparative evaluation of isoflurane and sevoflurane in avian patients.

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.

Patients with COVID-19: are current isolation guidelines effective enough?

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

相关实验视频

在老年人中存在阳离子缺口.

相关概念视频

相关文章

Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET.

Comparative evaluation of isoflurane and sevoflurane in avian patients.

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.

Patients with COVID-19: are current isolation guidelines effective enough?

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.